natgillin/translations-raw huggingface dataset:
El médico encargado del tratamiento debe vigilar con regularidad el desarrollo de los niños que toman Siklos.
The growth of children using Siklos should be regularly monitored by the treating doctor.
El paquete de información al paciente debe contener los siguientes elementos clave:
The patient information pack should contain the following key elements:
El poder teratógeno se caracterizó por osificación parcial de los huesos del cráneo, ausencia de las cuencas oculares, hidrocefalia, esternebras bífidas, ausencia de vértebras lumbares.
Teratogenicity was characterised by partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae.
El principio activo de Siklos se elimina por la leche materna.
The active substance of Siklos passes into human breast-milk.
El principio activo es la hidroxicarbamida.
The active substance is hydroxycarbamide.
el recovery
0.011-0.032
El relator reconoce que estos resultados pueden variar con el análisis final.
The rapporteur acknowledges that these results may vary with the final analysis.
El TAC realizará las actividades e intervenciones de farmacovigilancia necesarias según lo acordado en la versión del PGR incluido en el Módulo 1.8.2 de la Autorización de Comercialización y en cualquier actualización del PGR que se acuerde posteriormente.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
El tiempo necesario para alcanzar la concentración plasmática máxima y el porcentaje de dosis eliminado por la orina fueron superiores en niños que en adultos.
The time to reach maximum plasma concentration and the percentage of the dose excreted in urine were increased in children compared to adults.
El Titular de la Autorización de Comercialización (TAC) presentará los informes periódicos de seguridad para este medicamento de conformidad con las exigencias establecidas en la lista de fechas de referencia de la Unión (lista EURD) prevista en el artículo 107ter, párrafo 7, de la Directiva 2001/83/CE y publicada en el portal web europeo sobre medicamentos.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
El titular de la autorización de comercialización deberá cerciorarse de que, antes del lanzamiento, todos los médicos que vayan a prescribir Siklos dispongan de un paquete de información al médico que contenga lo siguiente:
The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe Siklos are provided with a physician information pack containing the following:
El tratamiento con Siklos debe ser iniciado por un médico que tenga experiencia en el tratamiento de la anemia drepanocítica.
Treatment with Siklos should be initiated by a physician experienced in the management of Sickle Cell Syndrome.
El tratamiento con Siklos requiere un control clínico estricto.
Treatment with Siklos requires close clinical monitoring.
El tratamiento con Siklos se puede reanudar con una dosis un poco más baja (ver sección 4.2).
Siklos therapy can then be re-initiated at a lower dose (see section 4.2).
El tratamiento de la sobredosis consiste en lavado gástrico seguido de tratamiento sintomático y control de la función de la médula ósea.
Treatment of overdose consists of gastric lavage, followed by symptomatic treatment and control of bone marrow function.
El uso simultáneo de hidroxicarbamida con una vacuna con virus vivos puede potenciar la replicación del virus de la vacuna y/o aumentar la reacción adversa al virus de la vacuna, porque puede que los mecanismos de defensa normales estén suprimidos por la hidroxicarbamida.
Concomitant use of hydroxycarbamide with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase the adverse reaction of the vaccine virus, because normal defence mechanisms may be suppressed by hydroxycarbamide therapy.
El uso simultáneo de hidroxicarbamida y otros medicamentos mielosupresores o radioterapia puede aumentar la depresión medular, los trastornos digestivos o la mucositis.
Concurrent use of hydroxycarbamide and other myelosuppressive medicinal products or radiation therapy may increase bone marrow depression, gastro-intestinal disturbances or mucositis.
El volumen de distribución en estado de equilibrio ajustado en función de la biodisponibilidad es de 0,57 l/kg en pacientes con anemia drepanocítica (lo que supone aproximadamente 72 l en niños y 90 l en adultos).
The volume of distribution at steady state adjusted for bioavailability is 0.57 l/kg in patients with Sickle Cell Syndrome (amounting to approximately 72 and 90 l in children and adults, respectively).
El volumen de distribución estimado de hidroxicarbamida es aproximadamente igual que el de agua total del organismo.
The estimated volume of distribution of hydroxycarbamide approximates total body water.
EL-123 51 Athen,
EL-12351
EL-15351 Pallini Attiki Grækenland
EL-15351 Pallini Attiki Greece
EL-194 00 Koropi Grækenland
194 00 Koropi Greece
Elanco Animal Health Priestley Road Basingstoke Hampshire
Priestley Road Basingstoke Hampshire RG24 9NL
Elanco Europe Ltd.
Marketing authorisation holder Elanco Europe Ltd.
Elanco Europe Ltd., Lilly House, Priestley Road, Basingstoke, RG24 9NL , Storbritannien
Elanco Europe Ltd., Lilly House, Priestley Road, Basingstoke, RG24 9NL ,UNITED KINGDOM
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue Frankrig
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue FRANCE
Elanco France S.A.S 26 Rue de la Chapelle, F-68330 Huningue, Frankrig.
26 Rue de la Chapelle 68330 Huningue FRANCE
Elanco France S.A.S 26, Rue de la Chapelle 68330 Huningue Frankrig
26, Rue de la Chapelle 68330 Huningue FRANCE
Elanco France S.A.S 26, Rue de la Chapelle 68330 Huningue Frankrig
Elanco France S.A.S 26, Rue de la Chapelle 68330 Huningue FRANCE
Elanco France S.A.S, 26 Rue de la Chapelle, 68330 Huningue, Frankrig
26 Rue de la Chapelle 68330 Huningue FRANCE
Elanco France S.A.S. 26 Rue de la Chapelle F-68330 Huningue Frankrig
Elanco France S.A. 26 Rue de la Chapelle F-68330 Huningue France
Elanco France S.A.S. 26 Rue de la Chapelle F-68330 Huningue Frankrig
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue France
Elanco France S.A.S. 26, Rue de la Chapelle 68330 Huningue Frankrig
Elanco France S.A.S. 26, Rue de la Chapelle 68330 Huningue France
Elaprase er godkendt under "særlige omstændigheder".
Elaprase has been authorised under ‘exceptional circumstances’.
Elaprases sikkerhed og virkning er blevet vist i tre kliniske studier: to randomiserede, placebokontrollerede kliniske studier (TKT008 og TKT024) med voksne og børn over 5 år og ét åbent sikkerhedsstudie (HGT-ELA-038) med børn i alderen mellem 16 måneder og 7,5 år.
The safety and efficacy of Elaprase has been shown in three clinical studies: two randomised, placebo- controlled clinical studies (TKT008 and TKT024) in adults and children above the age of 5 years and one open-label, safety study (HGT-ELA-038) in children between the age of 16 months and 7.5 years.
elastomer
ealed with
elastomer
olvent
elbasvir (50 mg enkeltdosis)
(50 mg single dose)
Elbasvir blokerer et protein, der hedder "NS5A", mens grazoprevir blokerer et enzym, der hedder "NS3/4A-protease".
Elbasvir blocks the action of a protein called ‘NS5A’, while grazoprevir blocks an enzyme called ‘NS3/4A protease’.
Elbasvir er aktivt in vitro mod genotype 1a NS5A-substitutionerne M28V og Q30L, genotype 1b- substitutionerne L28M/V, R30Q, L31V og Y93C og genotype 4-substitutionen M31V, der giver resistens over for andre NS5A-hæmmere.
Elbasvir is active in vitro against genotype 1a NS5A substitutions, M28V and Q30L, genotype 1b substitutions, L28M/V, R30Q, L31V, Y93C, and genotype 4 substitution, M31V, which confer resistance to other NS5A inhibitors.
elektive serotoningenoptagelseshæmmere (herunder, men ikke begrænset til fluoxetin og fluvoxamin), der normalt anvendes mod depression
a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
elektive serotoningenoptagelseshæmmere (inklusive, men ikke begrænset til fluoxetin eller fluvoxamin), medicin der normalt anvendes mod depression moclobemid, medicin mod depression.
a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, moclobemide, medicine to treat depression.
elektive serotoningenoptagelseshæmmere (inklusive, men ikke begrænset til fluoxetin og fluvoxamin), der normalt anvendes mod depression
a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression
elektive serotoningenoptagelseshæmmere (inklusive, men ikke begrænset til fluoxetin og fluvoxamin), der normalt anvendes mod depression
a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
elektive serotoningenoptagelseshæmmere (inklusive, men ikke begrænset til fluoxetin og fluvoxamin), der normalt anvendes mod depression,
a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
Elektrofysiologiske studier har vist, at ketoconazol hæmmer den hurtigt aktiverende komponent i hjertets forsinkede korrigerende kaliumstrøm, forlænger varigheden af aktionspotentialet og kan forlænge QT- intervallet.
Electrophysiological studies have shown that ketoconazole inhibits the rapidly activating component of the cardiac delayed rectifier potassium current, prolongs the action potential duration, and may prolong the QT interval.
Elektrofysiologiske undersøgelser viser, at nateglinid har 45–300 gange større selektivitet for pankreatiske β-celler i forhold til kardiovaskulære K+ATP-kanaler.
Electrophysiological studies demonstrate that nateglinide has 45–300-fold selectivity for pancreatic beta cell versus cardiovascular K+ATP channels.
Elektrokardiografiske forandringer (sinusbradykardi, forlængelse af PR- interval, forlængelse af QT-interval og forlængelse af QRS- kompleks) blev kun observeret i en indledende 2-ugers oral toksicitetsstudie udført på hunde.
Electrocardiographic changes (sinus bradycardia, prolongation of PR interval, prolongation of QT interval, and prolongation of QRS complex) were observed only in an initial 2 week oral toxicity study performed in dogs.
Elektrokardiogram (ekg)-anomalier: Arsentrioxid kan forårsage forlænget QT-interval og komplet atrieventrikulær blokering.
Electrocardiogram (ECG) Abnormalities: Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block.
Elektrokardiogram med QT forlængelse
Electrocardiogra m QT prolonged
Elektrokardiogram med QT-måling bør overvejes før administration af Tyverb og under hele behandlingsforløbet.
Electrocardiograms with QT measurement should be considered prior to administration of Tyverb and throughout treatment.
elektrokardiogram og monitoring
electrocardiogram monitoring and
Elektrokardiogram QT-forlængelse blev rapporteret hos 9,9 % af de patienter, der modtog delamanid som 100 mg to gange dagligt (hyppighedskategori almindeligt) sammenlignet med 3,8 % af patienter, der fik placebo + OBR.
Electrocardiogram QT prolonged was reported in 9.9% of patients receiving delamanid as 100 mg twice daily (frequency category common) compared to 3.8% of patients receiving placebo + OBR.
Elektrokardiogram QTc-forlængelse2 Palpitationer3
Electrocardiogram QTc prolonged2 Palpitations3
Elektrokardiogram ST segment depression
Electrocardiogram ST segment depression
Elektrokardiogram unormalt ST-T-segment
Electrocardiogram ST-T segment abnormal
elektrokardiogram,
System Organ Class
Elektrokardiogram- (Ekg-)undersøgelser
Electrocardiogram (ECG) investigations
Elektrokardiogram-ST-segmentændringer
Electrocardiogram ST segment changes
Elektrokardiogrammer bør overvåges hos alle patienter, særligt hos patienter med medfødt langt QT-syndrom, kongestivt hjertesvigt, bradyarytmier og patienter, der tager lægemidler, der vides at forlænge QT-intervallet, herunder Klasse Ia eller III antiarytmika.
Electrocardiograms should be monitored in all patients with a special attention for those with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, and those taking medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics.
Elektrokonvulsiv terapi (ECT)
ECT (electroconvulsive therapy)
Elektrokonvulsiv terapi (ECT):
ECT (electroconvulsive therapy)
Elektrolytdepletion, specielt hypokaliæmi, kan forstærkes;
Electrolyte depletion, particularly hypokalaemia, may be increased;
Elektrolytforstyrrelser
Electrolyte abnormalities
Elektrolytforstyrrelser (inklusive hypokaliæmi og hyponatriæmi, se pkt.
Electrolyte imbalance (including hypokalaemia and
elektrolytforstyrrelser, anoreksi hyperglykæmi
electrolyte imbalance, anorexia
elektrolytforstyrrelser, anoreksi, nedsat appetit, hypokalæmi, hypomagnesiæmi hyperglykæmi, hypoglykæmi
electrolyte imbalance, anorexia, decreased appetite, hypokalaemia, hypomagnesaemia hyperglycaemia, hypoglycaemia
elektrolytforstyrrelser, dyslipidæmi, appetitforstyrrelser, vægtændring
electrolyte imbalance, dyslipidaemia, appetite disorders, weight change
Elektrolytforstyrrelser, især hypokaliæmi, hypocalcæmi eller hypomagnesæmi.
Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
Elektrolytforstyrrelser, især hypokalæmi, hypokalcæmi eller hypomagnesæmi.
Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
Elektrolytforstyrrelser, især ukorrigeret hypokaliæmi
Electrolyte disturbances, particularly in uncorrected hypokalaemia
elektrolytforstyrrelser, især ukorrigeret hypokaliæmi
electrolyte disturbances, particularly uncorrected hypokalaemia
Elektromagnetisk miljø - vejledning
Electromagnetic environment - guidance
Elektromagnetisk miljø – vejledning
Electromagnetic environment – guidance
Elektromagnetisk strålingsspredning påvirkes af absorption og refleksion fra bygninger, genstande og mennesker.
Electromagnetic propagation is affected by absorption and reflection from structures, objects and people.
elektromekanisk dissociation (EMD)),
electromechanical dissociation (EMD)),
Elektronerne overføres derefter til jernatomerne i det unormale hæmoglobin, hvorved de omdannes til den normale ferro-form.
The electrons are then transferred to the iron atoms in the abnormal haemoglobin, converting them into the normal ferrous form.
Elektroretinografiske (ERG) ændringer (fald i a- og b-tak amplitude) blev rapporteret som en almindelig bivirkning hos patienter, som fik injiceret Jetrea; i størstedelen af tilfældene blev der også rapporteret dyskromatopsi.
Electroretinographic (ERG) changes (a- and b-wave amplitude decrease) have been reported as a common adverse reaction in patients injected with JETREA; in the majority of cases dyschromatopsia was also reported.
Elektrostatisk udladning (ESD)
Electrostatic discharge (ESD)
Elevación de las enzimas hepáticas
Elevated liver enzymes
ELF-niveauer af antigen alfa-1-proteinasehæmmer og af alfa-1-proteinasehæmmer: NE- komplekser steg fra baseline.
ELF levels of antigenic alpha1-proteinase inhibitor and alpha1-proteinase inhibitor: NE complexes increased from baseline.
Elfenbenshvid eller lyserød injektionsvæske, suspension
Off-white or pink suspension for injection
Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377
Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600
Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377
Tel: + 43-(0) 1 711 780
Eli Lilly and Company (Ireland) Limited Tel: +353 (0) 1 661 4377
Eli Lilly and Company (Ireland) Limited Tel: +353-(0) 1 661 4377
Eli Lilly and Company Limited Tel: + 44-(0) 1256 315000
Eli Lilly and Company Limited Tel: +44 (0) 1256 315000
Eli Lilly and Company Ltd Elanco Animal Health Priestley Road Basingstoke RG24 9NL Storbritannien
Eli Lilly and Company Ltd Elanco Animal Health Priestley Road Basingstoke RG24 9NL United Kingdom
Eli Lilly Danmark A/S Lyskær 3 E, 2. tv.
Elanco Animal Health A/S Eli Lilly Danmark A/S Lyskær 3 E, 2. tv.
Eli Lilly Danmark A/S Tlf.: +45 45 26 60 00
Eli Lilly Danmark A/S Tlf: +45 45 26 60 00
Eli Lilly Danmark A/S Tlf: +45 45 26 60 00
Eli Lilly Danmark A/S Tlf.: + 45 45 26 60 00
Eli Lilly Danmark A/S Tlf: +45 45 26 60 00
Eli Lilly Danmark A/S Tlf: + 45 45 26 60 00
Eli Lilly Ges. m.b.H.
Eli Lilly farmacevtska družba, d.o.o.
Eli Lilly Ges. m.b.H.
Eli Lilly Hrvatska d.o.o.
Eli Lilly Ges. m.b.H.
Lilly France S.A.S.
Eli Lilly Holdings Limited atstovybė Tel +370 (5) 2649600
Eli Lilly Holdings Limited atstovybė Tel: + 370 (5) 2649600
Eli Lilly Holdings Limited atstovybė Tel. + 370 (5) 2649600
Elanco Valquímica, S.A. Tel: + 34-91 623 1732
Eli Lilly Holdings Limited atstovybė Tel. +370 (5) 2649600
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6817 280
Eli Lilly Holdings Limited atstovybė Tel. +370 (5) 2649600
Tel: + 43-(0) 1 711 780
Eli Lilly Holdings Limited Eesti filiaal Tel: + 3726817280
Eli Lilly Holdings Limited Eesti filiaal Tel: + 372 6817 280
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6817 280
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6 817 280
Eli Lilly Holdings Limited Eesti filiaal Tel: +3726817 280
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6 817 280
Eli Lilly Holdings Limited pārstāvniecība
Eli Lilly Ges. m.b.H.
Eli Lilly Holdings Limited pārstāvniecība Latvijā
Eli Lilly farmacevtska družba, d.o.o.
Eli Lilly Holdings Limited pārstāvniecība Latvijā
Eli Lilly Ges. m.b.H.
Eli Lilly Holdings Limited pārstāvniecība Latvijā
Lilly France S.A.S.
Eli Lilly Holdings Limited, pārstāvniecība Latvijā Tel: + 371 6 7364000
Eli Lilly Holdings Limited, pārstāvniecība Latvijā Tel: + 371 67364000
Eli Lilly Hrvatska d.o.o.
Lilly France S.A.S.
Eli Lilly Hrvatska d.o.o.
Lilly France SAS
Eli Lilly Hrvatska d.o.o.
Lilly Hungária Kft.
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Eli Lilly Holdings Limited Eesti filiaal Tel: +372 6817 280
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Eli Lilly Nederland B.V. Tel: + 31(0) 30 6025800
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly Italia S.p.A. Tel: + 39- 055 42571
Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600
Eli Lilly Italia S.p.A. Via Gramsci 731/733 50019, Sesto Fiorentino Firenze (FI)
Via Gramsci 731/733 50019, Sesto Fiorentino Firenze (FI)
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Firenze, Italien.
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy,
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Firenze, Italien.
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy.
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italien.
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy,
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Florentino, Firenze, Italien.
Eli Lilly Italia S.p.A., Via A. Gramsci 731-733, 50019 Sesto Fiorentino, Florence, Italy.
Eli Lilly Italia S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italien.
Eli Lilly Italia S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italy,
Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino (FI), Italien.
Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino (FI), Italy.
Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italien
Eli Lilly Italia S.p.A.,Via Gramsci 731/733, 50019, Sesto Fiorentino, Firenze (FI), Italy
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht Holland
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht The Netherlands
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht, Holland
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht The Netherlands
Eli Lilly Nederland B.V. Tel: + 31(0)30 6025800
Eli Lilly Nederland B.V. Tel: + 31 (0)30 6025800
Eli Lilly Nederland B.V. Tel: + 31(0)30 6025800
Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht,, The Netherlands
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
Eli Lilly Nederland B V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00
Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351-21-4126600
Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00
Tel: +48 (0) 22 440 33 00
Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00
Tel: +48 22 440 33 00
Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00
ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600
Eli Lilly Polska Sp. z o.o.
Eli Lilly farmacevtska družba, d.o.o.
Eli Lilly Polska Sp. z o.o.
Lilly S.A. Eli Lilly Polska Sp. z o.o.
Eli Lilly Polska Sp. z o.o.
Phadisco Ltd
Eli Lilly Regional Operations GmbH
Eli Lilly Regional Operations GmbH Elanco Animal Health
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Wien, Østrig
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Vienna, Austria.
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Wien, Østrig.
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Vienna, Austria.
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly Ges.m.b.H.
Eli Lilly S.A. Dunderrow Kinsale County Cork Irland
Eli Lilly S.A. Dunderrow Kinsale County Cork Ireland
Eli Lilly Sweden AB Tel: + 46(0)8 7378800
Eli Lilly Sweden AB Tel: + 46 (0)8 7378800
Eli Lilly Sweden AB Tel: + 46-(0) 8 737 88 00
Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Eli Lilly Holdings Limited pārstāvniecība Latvijā Tel: +371 67364000
Eli Lilly, farmacevtska družba, d.o.o Tel: +386 (0)1 580 00 10
Eli Lilly farmacevtska družba, d.o.o Tel: + 386 (0)1 580 00 10
Eliglustat bør ikke bruges samtidig med lægemidler, der kan have en indvirkning på leverenzymer, der spiller en rolle for metabolismen af eliglustat.
Eliglustat should not be used concomitantly with medicines that may have an impact on liver enzymes that play a role in the metabolism of eliglustat.
Eliglustat er kontraindiceret til patienter, som har gennemsnitlig eller omfattende CYP2D6 metabolisering, som tager en stærk eller moderat CYP2D6-hæmmer samtidigt med en stærk eller moderat CYP3A-hæmmer.
Eliglustat is contraindicated in patients who are CYP2D6 Intermediate Metabolisers or Extensive Metabolisers who are taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor.
Eliglustat er også kontraindiceret til patienter, som har dårlig CYP2D6 metabolisering, og som tager en stærk CYP3A-hæmmer.
Eliglustat is also contraindicated in patients who are CYP2D6 poor metabolisers taking a strong CYP3A inhibitor.
Eliminación
Elimination
Eliminatie
Elimination
Elimination
Elimination:
Elimination
Elimination‌‌‌‌‌
Elimination
Incompatibilities
Elimination
UElimination